Durable protective efficiency provide by mRNA vaccines require robust immune memory to antigens and weak immune memory to lipid nanoparticles
Source abstract
Abstract
-LNPs immunity after repeated administration, thereby reducing vaccine effectiveness. To overcome these challenges, we developed a new type of LNPs vaccine (SAPC-LNPs) which was co-modified with sialic acid (SA) - lipid derivative and cleavable PEG - lipid derivative. This kind of mRNA vaccine can target dendritic cells (DCs) and rapidly escape from early endosomes (EE) and lysosomes with a total endosomal escape rate up to 98 %. Additionally, the PEG component in SAPC-LNPs was designed to detach from the LNPs under the catalysis of carboxylesterase in vivo, which reduced the probability of PEG being attached to LNPs entering antigen-presenting cells. Compared with commercially formulated vaccines (1.5PD-LNPs), mice treated with SAPC-LNPs generated a more robust immune memory to tumor antigens and a weaker immune memory response to LNPs, and showed lower side effects and long-lasting protective efficiency. We also discovered that the anti-tumor immune memory formed by SAPC-LNPs mRNA vaccine was directly involved in the immune cycle to rattack tumor. This immune memory continued to strengthen with multiple cycles, supporting that the immune memory should be incorporated into the theory of tumor immune cycle.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · SARS-CoV-2 and COVID-19 Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (43)
Show source-provided references
1. Lipid nanoparticles for mRNA delivery10.1038/s41578-021-00358-0 ↗
2. Lipid nanoparticles as delivery systems for RNA-based vaccines10.3390/pharmaceutics13020206 ↗
3. Drug delivery systems for RNA therapeutics
4. pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates10.1016/j.addr.2011.09.006 ↗
5. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage10.1016/j.jconrel.2013.07.026 ↗
6. Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-An innate immune system standpoint10.1016/j.smim.2017.08.015 ↗
7. Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine10.1021/acsnano.2c04543 ↗
8. Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines10.1038/s41577-022-00825-x ↗
9. Antibodies against poly(ethylene glycol) activate innate immune cells and induce hypersensitivity reactions to PEGylated nanomedicines10.1021/acsnano.2c12193 ↗
10. Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies10.1021/acsnano.1c05922 ↗
11. Pseudo-anaphylaxis to polyethylene glycol (PEG)-Coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions10.1021/acsnano.9b03942 ↗
12. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates10.1016/j.ymthe.2018.03.010 ↗
13. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing10.1038/s41565-020-0669-6 ↗
14. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery10.1038/s41596-022-00755-x ↗
15. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines10.1111/imr.13089 ↗
16. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver
17. Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects10.1038/s41571-023-00811-9 ↗
18. Lipid nanoparticles for mRNA delivery10.1038/s41578-021-00358-0 ↗
19. A preliminary study of the innate immune memory of Kupffer cells induced by PEGylated nanoemulsions10.1016/j.jconrel.2021.12.025 ↗
20. Manufacturing considerations for the development of lipid nanoparticles using microfluidics10.3390/pharmaceutics12111095 ↗
21. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles10.1073/pnas.1720542115 ↗
22. Rauch · 2017 · 89
23. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery10.1073/pnas.1306529110 ↗
24. Actin-regulated Siglec-1 nanoclustering influences HIV-1 capture and virus-containing compartment formation in dendritic cells
25. The role of sialic acid-binding immunoglobulin-like-lectin-1 (siglec-1) in immunology and infectious disease10.1080/08830185.2021.1931171 ↗
26. Sialoadhesin (CD169/Siglec-1) is an extended molecule that escapes inhibitory cis-interactions and synergizes with other macrophage receptors to promote phagocytosis10.1007/s10719-022-10097-1 ↗
27. Modular design of biodegradable ionizable lipids for improved mRNA delivery and precise cancer metastasis delineation in vivo10.1021/jacs.3c09143 ↗
28. Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity10.3389/fimmu.2013.00438 ↗
29. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?10.1016/S1471-4906(02)02281-0 ↗
30. Surveillance for adverse events after COVID-19 mRNA vaccination10.1001/jama.2021.15072 ↗
31. Adverse events with the Pfizer-BioNTech COVID-19 vaccine among Korean healthcare workers10.3349/ymj.2021.62.12.1162 ↗
32. Future considerations for the mRNA-lipid nanoparticle vaccine platform10.1016/j.coviro.2021.03.008 ↗
33. The form of PEG matters: PEG conjugated with lipids and not PEG alone could be the specific form involved in allergic reactions to COVID-19 vaccines10.1111/all.15187 ↗
34. Hypocomplementemic urticarial vasculitis case with hemophagocytic lymphohistiocytosis following SARS-CoV-2 mRNA vaccination10.1080/25785826.2023.2193286 ↗
35. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals10.1016/j.addr.2020.07.024 ↗
36. Maintaining safety with SARS-CoV-2 vaccines10.1056/NEJMra2035343 ↗
37. cBAF complex components and MYC cooperate early in CD8(+) T cell fate10.1038/s41586-022-04849-0 ↗
38. Trained immunity-related vaccines: innate immune memory and heterologous protection against infections10.1016/j.molmed.2022.03.009 ↗
39. Accelerated blood clearance of lipid nanoparticles entails a biphasic humoral response of B-1 followed by B-2 lymphocytes to distinct antigenic moieties10.4049/immunohorizons.1900029 ↗
40. Anti-PEG antibodies before and after a first dose of Comirnaty® (mRNA-LNP-based SARS-CoV-2 vaccine)10.1016/j.jconrel.2022.12.039 ↗
41. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 201910.1093/cid/ciaa344 ↗
42. SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals10.1016/j.ebiom.2022.103888 ↗
43. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles10.1038/mtna.2013.66 ↗